Gordan on Growing the Infrastructure for In-House Genomic Testing
Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.
Related Articles
Pacritinib and Momelotinib Display Positive Real-World Impact on Anemia and Transfusion Needs in Myelofibrosis
Pacritinib and momelotinib both demonstrated favorable real-world effects on anemia and transfusion requirements among patients with myelofibrosis.
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
Generic Platinum Chemotherapy Shortages Did Not Increase Deaths
A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage…
Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
European Commission Approves Lazertinib Plus Amivantamab in First-Line EGFR-Mutated NSCLC
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
FDA Grants Priority Review to Avutometinib Plus Defactinib for KRAS+ Recurrent Low-Grade Serous Ovarian Cancer
The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.
A “Rock Star” in Patient-Reported Outcomes, Is Listening
Basch, an oncologist and researcher who moonlights as a bass player, is in tune with colleagues and patients.
Dr Salani on Managing Mirvetuximab Soravtansine–Associated Ocular Toxicities in Ovarian Cancer
Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.